This document addresses the use of pharmacokinetic-pharmacodynamic analyses to identify potentially eficacious dose regimens of antibacterial agents. It applies also to antimycobacterial and antifungal agents.
Keywords: Epidemiologic cut-off value, exposure-response relationship, minimal inhibitory concentration, pharmacokinetic-pharmacodynamic index, magnitude, target, probability of target attainment, wild-type distribution
Current effective version
Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products
This Guideline replaces the Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CPMP/EWP/2655/99). The Guideline has been developed to outline the regulatory expectations for application dossiers and reflects both the scientific advances in the field that have implications for antimicrobial agent development programmes and the regulatory experience since the adoption of the 'Points to consider'.
English (EN) (198.71 KB - PDF)
Document history - Revision 1 (current)
Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products
This Guideline replaces the Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CPMP/EWP/2655/99). The Guideline has been developed to outline the regulatory expectations for application dossiers and reflects both the scientific advances in the field that have implications for antimicrobial agent development programmes and the regulatory experience since the adoption of the 'Points to consider'.
English (EN) (198.71 KB - PDF)
Overview of comments received on 'Draft guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products’ (EMA/CHMP/594085/2015)
English (EN) (470.9 KB - PDF)
Draft guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products
This guideline replaces the 'Points to consider' on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CHMP/EWP/2655/99). The Guideline has been developed to outline the regulatory expectations for application dossiers and reflects both the scientific advances in the field of pharmacometrics that have implications for antimicrobial agent development programmes and the regulatory experience since the adoption of the 'Points to consider'.
English (EN) (219.68 KB - PDF)
Draft concept paper on revision of the points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CHMP/EWP/2655/99) and conversion to a CHMP guideline
This concept paper proposes a revision of the CHMP’s points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CPMP/EWP/2655/99) and its conversion into a full guideline.
English (EN) (100.98 KB - PDF)
Document history - First version
Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products
English (EN) (86 KB - PDF)
Related content
- Clinical efficacy and safety: anti-infectives for systemic use
- Directive 2001/83/EC
- Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections
- Evaluation of medicinal products indicated for the treatment of bacterial infections
- Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function
- Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function
- ICH E1 Population exposure: the extent of population exposure to assess clinical safety
- ICH E4 Dose response information to support drug registration
- ICH E6 (R1) Good clinical practice
- ICH E8 General considerations for clinical trials
- ICH E11 Clinical investigation of medicinal products in the paediatric population
- Investigation of drug interactions
- Role of pharmacokinetics in the development of medicinal products in the paediatric population